Andrew Uzilov

Sema4 (United States)

Papers

2

Total Citations

145

H-Index

2

About

Andrew Uzilov is a pioneering researcher at the intersection of functional genomics and personalized oncology, best known for developing innovative, organism-based drug screening platforms that translate directly into life-saving clinical interventions. His primary research areas include rare cancers, precision medicine, and high-throughput therapeutic screening using model organisms. Uzilov’s landmark 2019 study (107 citations) introduced a personalized platform using Drosophila to identify trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer, resulting in a dramatic 11-month partial response. He further advanced this approach in a 2021 study (38 citations) targeting adenoid cystic carcinoma, a rare salivary gland cancer with limited treatment options, demonstrating that fly-based avatars can uncover effective therapies for notoriously difficult-to-treat malignancies. By bridging the gap between bench science and bedside application, Uzilov has established a paradigm for functional precision medicine, offering hope to patients with ultra-rare or genomically complex cancers where conventional targeted therapies fail. His work represents a powerful fusion of evolutionary biology and clinical oncology.

Research Focus

Key Achievements

2
H-Index
2
Papers
145
Total Citations
73
Avg Citations/Paper
🏆 Most Cited Paper
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
107 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 31
🏛 Institutions: Sema4 (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago